Objective: To analyze the clinical efficacy of the traditional Chinese medicine formula WD3 (WD3)combined with carrilizumab in the treatment of advanced esophageal cancer.Methods: A total of 86 patients with advanced esophageal cancer admitted to the Jiangyin Hospital of Traditional Chinese Medicine from September 2022 to August 2024 were divided into observation group (43 cases,WD3 combined with carrilizumab were used for treatment)and control group (43 cases, carrilizumab was used for treatment) by random number table method. TCM symptom score, quality of life, clinical efficacy, tumor markers, immune function, adverse reactions and prognosis were compared between the two groups.Results: After treatment, the scores of TCM symptoms in 2 groups were decreased(P < 0.05), and the scores in observation group were lower (P < 0.05). After treatment, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (QLQ - C30) score was increased in both groups(P < 0.05), and higher in observation group (P < 0.05). The objective remission rate and disease control rate of observation group were higher than control group (P <0.05). After treatment, the levels of keratin19 fragment antigen 21 -1 (CYFRA21 - 1), carbohydrate antigen 199 (CA199) and squamous cell carcinoma associated antigen (SCC- Ag) in serum of 2 groups were decreased (P < 0.05), and the levels were lower in observation group (P < 0.05). After treatment, the levels of CD4 ⁺/CD8 ⁺, CD4 ⁺ and CD3 ⁺ were increased in 2 groups (P < 0.05), and higher in observation group (P < 0.05). There were no significant differences in the total incidence of class I to Ⅳ adverse reactions such as thrombocytopenia, rash, liver function injury and gastrointestinal reactions between the two groups(P > 0.05). After one year of follow - up, there were 1 case lost to follow - up in the observation group and 2 cases lost to follow - up in the control group, resulting in a follow - up rate of 96.51% (83/86), and the survival rate was 83.33% (35/42) in the observation group and 63.41% (26/41) in the control group. The survival curve of observation group was better than control group (P <0.05).Conclusion: In patients with advanced esophageal cancer, the combination of WD3 and carrellizumab has significant therapeutic effect, which can improve the quality of life and immune function of patients, reduce the level of tumor markers, is safe and reliable, and can prolong the survival time of patients.

WD3  /  Carrilizumab  /  Esophageal cancer  /  Immune function  /  Tumor markers